|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Einhorn LH: First-line chemotherapy for
non-small-cell lung cancer: Is there a superior regimen based on
histology? J Clin Oncol. 26:3485–3486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zugazagoitia J, Ponce S and Paz-Ares L:
Necitumumab for first-line treatment of advanced, squamous,
non-small-cell lung cancer: A relevant step forward? Transl Lung
Cancer Res. 5:95–97. 2016.PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Drilon A, Rekhtman N, Ladanyi M and Paik
P: Squamous-cell carcinomas of the lung: Emerging biology,
controversies, and the promise of targeted therapy. Lancet Oncol.
13:e418–e426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xia L, Su X, Shen J, Meng Q, Yan J, Zhang
C, Chen Y, Wang H and Xu M: ANLN functions as a key candidate gene
in cervical cancer as determined by integrated bioinformatic
analysis. Cancer Manag Res. 10:663–670. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cui X, Yi Q, Jing X, Huang Y, Tian J, Long
C, Xiang Z, Liu J, Zhang C, Tan B, et al: Mining prognostic
significance of MEG3 in human breast cancer using bioinformatics
analysis. Cell Physiol Biochem. 50:41–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shao Y, Liang B, Long F and Jiang SJ:
Diagnostic MicroRNA biomarker discovery for non-small-cell lung
cancer adenocarcinoma by integrative bioinformatics analysis.
Biomed Res Int. 2017:25630852017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piao J, Sun J, Yang Y, Jin T, Chen L and
Lin Z: Target gene screening and evaluation of prognostic values in
non-small cell lung cancers by bioinformatics analysis. Gene.
647:306–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song YJ, Tan J, Gao XH and Wang LX:
Integrated analysis reveals key genes with prognostic value in lung
adenocarcinoma. Cancer Manag Res. 10:6097–6108. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou LN, Li SC, Li XY, Ge H and Li HM:
Identification of differential protein-coding gene expressions in
early phase lung adenocarcinoma. Thorac Cancer. 9:234–240. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41:D991–D995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davis S and Meltzer PS: GEOquery: A bridge
between the Gene Expression Omnibus (GEO) and BioConductor.
Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang da DW, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bader GD and Hogue CW: An automated method
for finding molecular complexes in large protein interaction
networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT and
Lin CY: cytoHubba: Identifying hub objects and sub-networks from
complex interactome. BMC Syst Biol. 8 (Suppl 4):S112014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maere S, Heymans K and Kuiper M: BiNGO: A
Cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goldman M, Craft B, Zhu J and Haussler D:
Abstract 2584: The UCSC Xena system for cancer genomics data
visualization and interpretation. Cancer Res. 77 (Suppl
13):S25842017.
|
|
25
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Smits VA and Medema RH: Checking out the
G(2)/M transition. Biochim Biophys Acta. 1519:1–12. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song Y, Zhao C, Dong L, Fu M, Xue L, Huang
Z, Tong T, Zhou Z, Chen A, Yang Z, et al: Overexpression of cyclin
B1 in human esophageal squamous cell carcinoma cells induces tumor
cell invasive growth and metastasis. Carcinogenesis. 29:307–315.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aaltonen K, Amini RM, Heikkilä P,
Aittomäki K, Tamminen A, Nevanlinna H and Blomqvist C: High cyclin
B1 expression is associated with poor survival in breast cancer. Br
J Cancer. 100:1055–1060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Begnami MD, Fregnani JH, Nonogaki S and
Soares FA: Evaluation of cell cycle protein expression in gastric
cancer: Cyclin B1 expression and its prognostic implication. Hum
Pathol. 41:1120–1127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu
D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage
non-small cell lung cancer and its clinical implication. Cancer
Res. 60:4000–4004. 2000.PubMed/NCBI
|
|
32
|
Cooper WA, Kohonen-Corish MR, McCaughan B,
Kennedy C, Sutherland RL and Lee CS: Expression and prognostic
significance of cyclin B1 and cyclin A in non-small cell lung
cancer. Histopathology. 55:28–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suzuki H, Graziano DF, McKolanis J and
Finn OJ: T cell-dependent antibody responses against aberrantly
expressed cyclin B1 protein in patients with cancer and
premalignant disease. Clin Cancer Res. 11:1521–1526. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Egawa H, Furukawa K, Preston D, Funamoto
S, Yonehara S, Matsuo T, Tokuoka S, Suyama A, Ozasa K, Kodama K and
Mabuchi K: Radiation and smoking effects on lung cancer incidence
by histological types among atomic bomb survivors. Radiat Res.
178:191–201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pines J and Hunter T: Isolation of a human
cyclin cDNA: Evidence for cyclin mRNA and protein regulation in the
cell cycle and for interaction with p34cdc2. Cell. 58:833–846.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yoshida T, Tanaka S, Mogi A, Shitara Y and
Kuwano H: The clinical significance of Cyclin B1 and Wee1
expression in non-small-cell lung cancer. Ann Oncol. 15:252–256.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee HH, Elia N, Ghirlando R,
Lippincott-Schwartz J and Hurley JH: Midbody targeting of the ESCRT
machinery by a noncanonical coiled coil in CEP55. Science.
322:576–580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fabbro M, Zhou BB, Takahashi M, Sarcevic
B, Lal P, Graham ME, Gabrielli BG, Robinson PJ, Nigg EA, Ono Y and
Khanna KK: Cdk1/Erk2- and Plk1-dependent phosphorylation of a
centrosome protein, Cep55, is required for its recruitment to
midbody and cytokinesis. Dev Cell. 9:477–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kalimutho M, Sinha D, Jeffery J, Nones K,
Srihari S, Fernando WC, Duijf PH, Vennin C, Raninga P, Nanayakkara
D, et al: CEP55 is a determinant of cell fate during perturbed
mitosis in breast cancer. EMBO Mol Med. 10:e85662018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jeffery J, Sinha D, Srihari S, Kalimutho M
and Khanna KK: Beyond cytokinesis: The emerging roles of CEP55 in
tumorigenesis. Oncogene. 35:683–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen CH, Shiu LY, Su LJ, Huang CY, Huang
SC, Huang CC, Yin YF, Wang WS, Tsai HT, Fang FM, et al: FLJ10540 is
associated with tumor progression in nasopharyngeal carcinomas and
contributes to nasopharyngeal cell proliferation, and metastasis
via osteopontin/CD44 pathway. J Transl Med. 10:932012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ,
Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA
upregulates FLJ10540 and modulates migration and invasion of lung
cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ma XP, Zhang W, Wu BQ and Qin J:
Correlations between mRNA levels of centrosomal protein 55 (CEP55)
and clinical features of patients with lung cancer. Med Sci Monit.
24:3093–3097. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Halasi M and Gartel AL: FOX(M1) news-it is
cancer. Mol Cancer Ther. 12:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gentles AJ, Newman AM, Liu CL, Bratman SV,
Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The
prognostic landscape of genes and infiltrating immune cells across
human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin
TV and Kalinichenko VV: Foxm1 transcription factor is required for
the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Oncogene. 33:5391–5396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Leung TW, Lin SS, Tsang AC, Tong CS, Ching
JC, Leung WY, Gimlich R, Wong GG and Yao KM: Over-expression of
FoxM1 stimulates cyclin B1 expression. FEBS Lett. 507:59–66. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gemenetzidis E, Bose A, Riaz AM, Chaplin
T, Young BD, Ali M, Sugden D, Thurlow JK, Cheong SC, Teo SH, et al:
FOXM1 upregulation is an early event in human squamous cell
carcinoma and it is enhanced by nicotine during malignant
transformation. PLoS One. 4:e48492009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Intuyod K, Saavedra-García P, Zona S, Lai
CF, Jiramongkol Y, Vaeteewoottacharn K, Pairojkul C, Yao S, Yong
JS, Trakansuebkul S, et al: FOXM1 modulates 5-fluorouracil
sensitivity in cholangiocarcinoma through thymidylate synthase
(TYMS): Implications of FOXM1-TYMS axis uncoupling in 5-FU
resistance. Cell Death Dis. 9:11852018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sales GR and Vagnarelli P: Ki-67: More
hidden behind a ‘classic proliferation marker’. Trends Biochem Sci.
43:747–748. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sobecki M, Mrouj K, Colinge J, Gerbe F,
Jay P, Krasinska L, Dulic V and Fisher D: Cell-cycle regulation
accounts for variability in Ki-67 expression levels. Cancer Res.
77:2722–2734. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Miller I, Min M, Yang C, Tian C, Gookin S,
Carter D and Spencer SL: Ki67 is a graded rather than a binary
marker of proliferation versus quiescence. Cell Rep.
24:1105–1112.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Warth A, Cortis J, Soltermann A, Meister
M, Budczies J, Stenzinger A, Goeppert B, Thomas M, Herth FJ,
Schirmacher P, et al: Tumour cell proliferation (Ki-67) in
non-small cell lung cancer: A critical reappraisal of its
prognostic role. Br J Cancer. 111:1222–1229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Carreras CW and Santi DV: The catalytic
mechanism and structure of thymidylate synthase. Annu Rev Biochem.
64:721–762. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Takezawa K, Okamoto I, Tsukioka S, Uchida
J, Kiniwa M, Fukuoka M and Nakagawa K: Identification of
thymidylate synthase as a potential therapeutic target for lung
cancer. Br J Cancer. 103:354–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Foekens JA, Romain S, Look MP, Martin PM
and Klijn JG: Thymidine kinase and thymidylate synthase in advanced
breast cancer: Response to tamoxifen and chemotherapy. Cancer Res.
61:1421–1425. 2001.PubMed/NCBI
|
|
58
|
Squires MR III, Fisher SB, Fisher KE,
Patel SH, Kooby DA, El-Rayes BF, Staley CR III, Farris AR III and
Maithel SK: Differential expression and prognostic value of ERCC1
and thymidylate synthase in resected gastric adenocarcinoma.
Cancer. 119:3242–3250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sun JM, Han J, Ahn JS, Park K and Ahn MJ:
Significance of thymidylate synthase and thyroid transcription
factor 1 expression in patients with nonsquamous non-small cell
lung cancer treated with pemetrexed-based chemotherapy. J Thorac
Oncol. 6:1392–1399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han
J, Park K and Ahn MJ: Pemetrexed plus cisplatin versus gemcitabine
plus cisplatin according to thymidylate synthase expression in
nonsquamous non-small-cell lung cancer: A biomarker-stratified
randomized phase II trial. J Clin Oncol. 33:2450–2456. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Beermann J, Piccoli MT, Viereck J and Thum
T: Non-coding RNAs in development and disease: Background,
mechanisms, and therapeutic approaches. Physiol Rev. 96:1297–1325.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sui J, Xu SY, Han J, Yang SR, Li CY, Yin
LH, Pu YP and Liang GY: Integrated analysis of competing endogenous
RNA network revealing lncRNAs as potential prognostic biomarkers in
human lung squamous cell carcinoma. Oncotarget. 8:65997–66018.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Jiang R, Zhao C, Gao B, Xu J, Song W and
Shi P: Mixomics analysis of breast cancer: Long non-coding RNA
linc01561 acts as ceRNA involved in the progression of breast
cancer. Int J Biochem Cell Biol. 102:1–9. 2018. View Article : Google Scholar : PubMed/NCBI
|
